Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
120.69
+4.58 (3.94%)
Feb 21, 2025, 4:00 PM EST - Market closed
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of December 31, 2024. The number of employees increased by 400 or 28.57% compared to the previous year.
Employees
1,800
Change (1Y)
400
Growth (1Y)
28.57%
Revenue / Employee
$1,308,500
Profits / Employee
$189,611
Market Cap
12.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,800 | 400 | 28.57% |
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
NBIX News
- 1 day ago - Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program - PRNewsWire
- 14 days ago - Why Is Neurocrine Biosciences Stock Trading Lower On Friday? - Benzinga
- 15 days ago - Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 - PRNewsWire
- 18 days ago - Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval - Seeking Alpha
- 22 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results - PRNewsWire
- 25 days ago - Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults - PRNewsWire
- 25 days ago - Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) - PRNewsWire